The stability factor: importance in formulation development
- PMID: 12463418
- DOI: 10.2174/1389201023378229
The stability factor: importance in formulation development
Abstract
Efficient development of stable formulations of protein pharmaceuticals requires an intimate knowledge of the protein and its chemical and physical properties. In particular, understanding the mechanisms by which a protein could degrade is critical for designing and testing formulations. This review describes the major pathways by which proteins can degrade, including denaturation, aggregation, oxidation, and interfacial damage. The methods to detect the degradation are covered, along with generalized strategies to retard or prevent each type of decomposition. Without an appreciation of the current best practices for devising stable formulations, the formulation process will be neither efficient nor optimal.
Similar articles
-
Analytical methods and formulation factors to enhance protein stability in solution.Arch Pharm Res. 2012 Nov;35(11):1871-86. doi: 10.1007/s12272-012-1103-x. Epub 2012 Dec 4. Arch Pharm Res. 2012. PMID: 23212628 Review.
-
Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.Expert Opin Drug Deliv. 2009 Nov;6(11):1219-30. doi: 10.1517/17425240903199143. Expert Opin Drug Deliv. 2009. PMID: 19678792 Review.
-
Chemical degradation of proteins in the solid state with a focus on photochemical reactions.Adv Drug Deliv Rev. 2015 Oct 1;93:2-13. doi: 10.1016/j.addr.2014.11.016. Epub 2014 Dec 4. Adv Drug Deliv Rev. 2015. PMID: 25481682 Review.
-
The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-77. Crit Rev Ther Drug Carrier Syst. 1993. PMID: 8124728 Review.
-
Preformulation studies as an essential guide to formulation development and manufacture of protein pharmaceuticals.Pharm Biotechnol. 2002;14:1-46. doi: 10.1007/978-1-4615-0549-5_1. Pharm Biotechnol. 2002. PMID: 12189723 Review. No abstract available.
Cited by
-
The use of epidermal growth factor in dermatological practice.Int Wound J. 2023 Aug;20(6):2414-2423. doi: 10.1111/iwj.14075. Epub 2022 Dec 30. Int Wound J. 2023. PMID: 36584669 Free PMC article. Review.
-
Bioactivity of WLBU2 peptide antibiotic in combination with bioerodible polymer.Int J Antimicrob Agents. 2011 Dec;38(6):530-3. doi: 10.1016/j.ijantimicag.2011.07.011. Epub 2011 Sep 15. Int J Antimicrob Agents. 2011. PMID: 21920706 Free PMC article.
-
Development of dextran nanoparticles for stabilizing delicate proteins.Nanoscale Res Lett. 2013 Apr 27;8(1):197. doi: 10.1186/1556-276X-8-197. Nanoscale Res Lett. 2013. PMID: 23622054 Free PMC article.
-
Investigation of purification process stresses on erythropoietin peptide mapping profile.Adv Biomed Res. 2015 May 29;4:114. doi: 10.4103/2277-9175.157836. eCollection 2015. Adv Biomed Res. 2015. PMID: 26261816 Free PMC article.
-
Coarse-grained strategy for modeling protein stability in concentrated solutions. III: directional protein interactions.Biophys J. 2007 Jun 15;92(12):4316-24. doi: 10.1529/biophysj.106.099085. Epub 2007 Mar 30. Biophys J. 2007. PMID: 17400697 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources